October 27, 2021
Solasia Pharma said on October 26 that it has terminated its license agreement with Meiji Seika Pharma for Japan rights to darinaparsin, a drug candidate for peripheral T-cell lymphoma (PTCL), while announcing a new pact with Nippon Kayaku. Solasia signed...read more